BeiGene, Ltd. (ONC) AI Stock Analysis

BeOne Medicines AG, an oncology company, discovers and develops cancer treatments in the United States, China, Europe, and internationally. Its commercial stage portfolio includes BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase for blood cancers, and TEVIMBRA, an anti-PD-1 antibody immunotherapy for solid tumors and blood cancers. Other commercial treatments include SYLVANT, BAITUOWEI, and PARTRUVIX. Its clinical pipeline features Sonrotoclax BGB-11417, BGB-16673, Zanidatamab, as well as multiple antibody-drug conjugates, bispecific antibodies, and targeted inhibitors across oncology indications. The company maintains collaboration agreements with Amgen, BMS, Bio-Thera, and EUSA.

BeiGene achieved a five-year revenue CAGR of 76.8% from FY2020 to FY2025. Annual revenue grew from $1.18B in FY2021 to $1.42B in FY2022, $2.46B in FY2023, $3.81B in FY2024, and $5.34B in FY2025, representing 40.2% growth in FY2025. Gross margin reached 87.5% in FY2025, while operating margin improved from -122.3% in FY2021 to 8.4% in FY2025. Net income turned profitable at $286.9M in FY2025 after a net loss of $644.8M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 29.6% year-over-year and quarterly earnings grew 166.7% year-over-year. TTM revenue reached $6.13B with an operating margin of 19.1%.

As of June 30, 2026, the company held $5.10B in cash and short-term investments against $1.14B in total debt, yielding net cash of $3.95B. Total assets stood at $9.18B and shareholders' equity was $5.17B. Liquidity remained solid with a current ratio of 3.40 and a debt-to-equity ratio of 0.22. In FY2025, operating cash flow reached $1.13B and free cash flow was $941.7M, while capital expenditures totaled $185.8M. Over five years, share count increased 21.9%.

At a last close of $369.06, ONC trades at a trailing P/E of 66.0x and a forward P/E of 35.2x, above the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its enterprise value of $38.33B reflects an EV/EBITDA of 33.7x compared to the peer median of 12.0x, and its price-to-sales of 6.9x compares to the peer median of 4.1x. The PEG ratio is 0.77. Over the past year, ONC returned 16.0% versus 16.8% for the S&P 500, and its five-year return was 3.0% compared to 83.0% for the index.

Wall Street analysts maintain 19 Strong Buy, 7 Buy, and 1 Hold ratings on ONC, with 0 Sell and 0 Strong Sell ratings. The mean price target is $436.46, representing an 18.3% premium over the last close of $369.06. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $6.77B and EPS of $7.64, representing 202.1% EPS growth. Across 17 analysts, next fiscal year estimates anticipate revenue of $7.78B. ONC beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of BeiGene, Ltd. (ONC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ONC income statement, ONC balance sheet, ONC key metrics, ONC analyst forecast, ONC chart. See the ONC stock overview for the latest quote and news.